Stockscreener 앱 받기
9.75
0.31%
-0.03
시간 외 거래:
9.75
전일 마감가:
$9.78
열려 있는:
$9.72
하루 거래량:
57,296
Relative Volume:
0.52
시가총액:
$140.58M
수익:
$166.88M
순이익/손실:
$-74.18M
주가수익비율:
-1.9231
EPS:
-5.07
순현금흐름:
$1.14M
1주 성능:
-2.60%
1개월 성능:
+3.72%
6개월 성능:
-32.90%
1년 성능:
-43.02%
1일 변동 폭
$9.72
$9.93
1주일 범위
$9.585
$10.17
52주 변동 폭
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
ANIK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.75 | 141.01M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Anika Therapeutics (NASDAQ:ANIK) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 EndofYear Setup & Technical Pattern Based Signals - newser.com
What dividend safety rating applies to Anika Therapeutics Inc. (AKP) stockTrade Ideas & Scalable Portfolio Growth Methods - newser.com
Key metrics from Anika Therapeutics Inc.’s quarterly data2025 Winners & Losers & Verified Technical Signals - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flows2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Why Anika Therapeutics Inc. stock could rally in 2025Weekly Profit Analysis & Breakout Confirmation Alerts - newser.com
Does Anika Therapeutics Inc. show high probability of reboundJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Why Anika Therapeutics Inc. stock could outperform in 2025Bear Alert & Low Risk High Win Rate Stock Picks - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.Inflation Watch & Long Hold Capital Preservation Plans - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Strategies to average down on Anika Therapeutics Inc.2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
How to escape a deep drawdown in Anika Therapeutics Inc.2025 Growth vs Value & Smart Allocation Stock Reports - newser.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a favorite amongst institutional investors who own 60% - Yahoo Finance
Using AI based signals to follow Anika Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Can Anika Therapeutics Inc. stock sustain revenue growth2025 Momentum Check & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Anika Therapeutics Inc. (AKP) stock benefit from sector leadershipMarket Performance Report & Daily Technical Forecast Reports - Fundação Cultural do Pará
Can Anika Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Macro Moves & Fast Gain Swing Alerts - Fundação Cultural do Pará
Is Anika Therapeutics Inc. stock attractive for growth ETFsWeekly Gains Summary & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer? - TipRanks
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
3.18%
1.86%
자본화:
|
볼륨(24시간):